The controversial role of B-vitamins in cardiovascular risk: An update

Archives of Cardiovascular Diseases

Volumn 102, Issue 12, 2009, Pages 847-854

  Ntaios, George ^a   Savopoulos, Christos ^a   Grekas, Dimitrios ^a   Hatzitolios, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

B vitamins; Cardiovascular risk; Coronary heart disease; Folic acid; Homocysteine; Stroke

Indexed keywords

CYANOCOBALAMIN; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHOTREXATE; PLACEBO; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOTHESIS; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; REVIEW; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

EID: 75149168269     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2009.07.002     Document Type: Review

References (99)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
2. Homocysteine, and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
3. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
4. Arnesen E, Refsum H, Bonaa KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
5. Bots ML, Launer U, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159:38-44.
6. Chambers JC, Obeid OA, Refsum H, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000;355:523-7.
7. Coull BM, Malinow MR, Beamer N, et al. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-6.
8. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B-vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998;98:204-10.
9. Genest Jr JJ, McNamara JR, Salem DN, et al. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-9.
10. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
11. Lindgren A, Brattstrom L, Norrving B, et al. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26:795-800.
12. Malinow MR, Ducimetiere P, Luc G, et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996;126:27-34.
13. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994;59:940-8.
14. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
15. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:412-7.
16. Silberberg J, Crooks R, Fryer J, et al. Gender differences and other determinants of the rise in plasma homocysteine after L-methionine loading. Atherosclerosis 1997;133:105-10.
17. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
18. Ubbink JB, Fehily AM, Pickering J, et al. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis 1998;140:349-56.
19. Verhoef P, Hennekens CH, Malinow MR, et al. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 1994;25:1924-30.
20. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-7.
21. Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: prospective study in middle-aged men. Heart 1999;82:448-54.
22. Bronstrup A. Effects of single and combined B-vitamin supplementation on homocysteine concentrations in different population groups [dissertation] Bonn. Germany: University of Bonn; 1998.
23. Brouwer IA, van Dusseldorp M, Thomas CM, et al. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Am J Clin Nutr 1999;69:99-104.
24. Cuskelly G, McNulty W, McPartlin J, et al. Plasma homocysteine response to folate intervention in young women. Ir J Med Sci 1995;164:3.
25. den Heijer M, Brouwer IA, Bos GM, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998;18:356-61.
26. Dierkes J. Vitamin requirements for the reduction of homocysteine blood levels in healthy young women [dissertation] Bonn. Germany: University of Bonn; 1995.
27. Dierkes J, Kroesen M, Pietrzik K. Folic acid and Vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women. Int J Vitam Nutr Res 1998;68:98-103.
28. Landgren F, Israelsson B, Lindgren A, et al. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995;237:381-8.
29. MacMahon M, Kirkpatrick C, Cummings CE, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the study of the effectiveness of additional reductions in cholesterol and homocysteine (Search). Nutr Metab Cardiovasc Dis 2000;10:195-203.
30. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-15.
31. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997;17:1157-62.
32. Naurath HJ, Joosten E, Riezler R, et al. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346:85-9.
33. Neal B, MacMahon S, Ohkubo T, et al. Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. Eur Heart J 2002;23:1509-15.
34. Ntaios GC, Savopoulos CG, Chatzinikolaou AC, et al. Vitamins and stroke: the homocysteine hypothesis still in doubt. Neurologist 2008;14:2-4.
35. Saltzman E, Mason JB, Jacques PF, et al. B-vitamin supplementation lowers homocysteine levels in heart disease. Clin Res 1994;42:172A.
36. Schorah CJ, Devitt H, Lucock M, et al. The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. Eur J Clin Nutr 1998;52:407-11.
37. Thambyrajah J, Landray MJ, Jones HJ, et al. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol 2001;37:1858-63.
38. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000;102:871-5.
39. Ubbink JB, van der Merwe A, Vermaak WJ, et al. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig 1993;71:993-8.
40. Ubbink JB, Vermaak WJ, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927-33.
41. van Oort FV, Melse-Boonstra A, Brouwer IA, et al. Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study. Am J Clin Nutr 2003;77:1318-23.
42. Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001;161:695-700.
43. Woodside JV, Yarnell JW, McMaster D, et al. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr 1998;67:858-66.
44. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 2000;26:341-8.
45. Bostom AG, Selhub J, Jacques PF, et al. Power shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med 2001;135:133-7.
46. Tchantchou F. Homocysteine metabolism and various consequences of folate deficiency. J Alzheimers Dis 2006;9:421-7.
47. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahy-drofolate reductase. Nat Genet 1995;10:111-3.
48. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
49. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37:1-31.
50. van der Put NM, van der Molen EF, Kluijtmans LA, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. QJM 1997;90:511-7.
51. Nordstrom M, Kjellstrom T. Age dependency of cys-tathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis 1992;94:213-21.
52. Wouters MG, Moorrees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-5.
53. Perry DJ. Hyperhomocysteinaemia. Baillieres Best Pract Res Clin Haematol 1999;12:451-77.
54. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999;354:219-20.
55. Daly D, Miller JW, Nadeau MR, et al. The effect of L-dopa administration and folate deficiency on plasma homocysteine concentrations in rats. J Nutr Biochem 1997;8:634-40.
56. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl 1996;57:S11-7.
57. Grekas D, Economou H, Makedou A, et al. Association between hyperhomocysteinemia and ultrasonographic atherosclerotic indices of carotid arteries in chronic hemodialysis patients. Nephron Clin Pract 2005;101:c180-6.
58. Refsum H, Heiland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther 1989;46:510-20.
59. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
60. Houston PE, Rana S, Sekhsaria S, et al. Homocysteine in sickle cell disease: relationship to stroke. Am J Med 1997;103:192-6.
61. Gisslinger H, Rodeghiero F, Ruggeri M, et al. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol 1999;105:551-5.
62. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
63. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202.
64. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82:806-12.
65. Jacques PF, Bostom AG, Wilson PW, et al. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001;73:613-21.
66. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006; 151:282-7.
67. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial [abstract]. Circulation 2002;106:3642.
68. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
69. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
70. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25.
71. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007;298:1163-70.
72. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008;300:795-804.
73. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299:2027-36.
74. Ntaios G, Savopoulos C, Karamitsos D. Effect of folic acid and B vitamins on cardiovascular disease in women. JAMA 2008;300:1409, 10 author reply.
75. Lange H, Suryapranata H. De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting N Engl J Med 2004;350:2673-81.
76. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: results of the Goes extension study. Heart 2005;91:1213-4.
77. Liem AH, van Boven AJ, Veeger NJ, et al. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomized pilot trial. Int J Cardiol 2004;93:175-9.
78. Mark SD, Wang W, Fraumeni Jr JF, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol 1996;143:658-64.
79. Righetti M, Serbelloni P, Milani S, et al. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006;24:379-86.
80. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002;288:973-9.
81. Wrone EM, Hornberger JM, Zehnder JL, et al. Randomized trial of folic acid for prevention of cardiovascular events in endstage renal disease. J Am Soc Nephrol 2004;15:420-6.
82. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006;47:1108-16.
83. Austen SK, Fassett RG, Geraghty DP, et al. Folate supplementation fails to affect vascular function and carotid artery intima-media thickness in cyclosporin A-treated renal transplant recipients. Clin Nephrol 2006;66:373-9.
84. Fernandez-Miranda C, Yebra M, Aranda JL, et al. Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease. Int J Cardiol 2007;118:345-9.
85. Hodis HN, Mack WJ, Dustin L, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke 2009;40:730-6.
86. Marcucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 2003;75:1551-5.
87. Ntaios G, Savopoulos C, Hatzitolios A, et al. Is there a beneficial effect of folic acid on carotid intima-media thickness? Int J Cardiol 2009;135:260-1.
88. Ntaios G, Savopoulos C, Karamitsos D, et al. The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: A randomized, placebo-controlled trial. Int J Cardiol 2009;online early view:doi:10.1016/j.ijcard.2009.01.023.
89. Potter K, Hankey GJ, Green DJ, et al. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc Disord 2008;8:24.
90. Till U, Rohl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12. Atherosclerosis 2005;181:131-5.
91. Tungkasereerak P, Ong-ajyooth L, Chaiyasoot W, et al. Effect of short-term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients. J Med Assoc Thai 2006;89:1187-93.
92. Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006;296:2720-6.
93. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82.
94. Yang Q, Botto LD, Erickson JD, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-43.
95. Ntaios G, Chatzinikolaou A, Savopoulos C, et al. Well done folate, the little boy was born healthy without spina bifida: but will he suffer a stroke when elderly? Eur J Intern Med 2009;20:2.
96. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 2006;354:1629-32.
97. Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006;26:2536-40.
98. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009;30:6-15.
99. Clarke R, Armitage J, Lewington S, et al. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis. Clin Chem Lab Med 2007;45:1575-81.